Prevention of liver transplant rejection

Prevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia...

Prevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver Prophylactic immunosuppression mitigates these destructive immune pathways to prevent graft dysfunction and ensure long-term allograft survival

This clinical management is essential in both adult and pediatric liver allograft recipients

This clinical management is essential in both adult and pediatric liver allograft recipients

Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia and arteriopathy

Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia and arteriopathy

Prophylactic immunosuppression mitigates these destructive immune pathways to prevent graft dysfunction and ensure long-term allograft survival